Maria Dampmann

Maria Dampmann

Auto-generated profile, based on publicly available information

Maria Dampmann

Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMaria Dampmann
Maria Dampmann
André GörgensAndré Görgens
André Görgens
MMMichael Möllmann
Michael Möllmann
FMFlorian Murke
Florian Murke
UDUlrich Dührsen
Ulrich Dührsen
JDJan Dürig
Jan Dürig
In order to accomplish their physiological functions leukocytes have the capability to migrate. As a prerequisite they need to adopt a polarized cell shape, forming a leading edge at the front and a uropod at rear pole. In this study we explored the capability of chronic lymphocytic leukaemia (CLL) cells to adopt this leukocyte-specific migration phenotype. Furthermore, we studied the impact of the Toll-like receptor 9 (TLR9) agonists CpGs type A, B and C and the antagonist oligodesoxynucleotide (ODN) INH-18 on the cell polarization and migration process of primary human CLL cells. Upon cultivation, a portion of purified CLL cells adopted polarized cell shapes spontaneously (range 10–38%). Stimulation with CpG ODNs type B (ODN 2006) and CpGs type C (ODN 2395) significantly increased the frequency of morphologically polarized CLL cells, while ODN INH-18 was hardly able to act antagonistically. Like in human hematopoietic stem and progenitor cells, in morphologically polarized CLL cells CXCR4 was redistributed to the leading edge and CD50 to the uropod. Coupled to the increased frequencies of morphologically polarized cells, CpGs type B and C stimulated CLL cells showed higher migration activities in vitro and following intravenous injection higher homing frequencies to the bone marrow of immunocompromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Thus, presumably independent of TLR-9 signaling, CpGs type B and C promote the cellular polarization process of CLL cells and their ability to migrate in vitro and in vivo.

10 July 2023 in EMBO Reports
Verified
Journal Article
Open access
BRBettina Röder
Bettina Röder
HFHannah Fahnenstiel
Hannah Fahnenstiel
SSSimon Schäfer
Simon Schäfer
BBBettina Budeus
Bettina Budeus
MDMaria Dampmann
Maria Dampmann
LNLars Nitschke
Lars Nitschke
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5 + B cells. BCR signaling is regulated by the inhibitory co‐receptor Siglec‐G and Siglec‐G‐deficient mice have an enlarged CD5 + B1a cell population. Here, we determine how Siglec‐G expression influences the severity of CLL. Our results show that Siglec‐G deficiency leads to earlier onset and more severe course of the CLL‐like disease in the murine Eμ‐TCL1 model. In contrast, mice overexpressing Siglec‐G on the B cell surface are almost completely protected from developing CLL‐like disease. Furthermore, we observe a downmodulation of the human ortholog Siglec‐10 from the surface of human CLL cells. These results demonstrate a critical role for Siglec‐G in disease progression in mice, and suggest that a similar mechanism for Siglec‐10 in human CLL may exist.

10 June 2025 in Leukemia & Lymphoma
Verified
Journal Article
Open access
MDMaria Dampmann
Maria Dampmann
BTBastian von Tresckow
Bastian von Tresckow
HRHans Christian Reinhardt
Hans Christian Reinhardt
RKRalf Küppers
Ralf Küppers
JTJulia von Tresckow
Julia von Tresckow
The B-cell antigen receptor (BCR) plays an essential role in the pathogenesis of B-cell malignancies such as chronic lymphocytic leukemia (CLL). CLL exhibits two main subtypes based on immunoglobulin heavy chain variable (IGHV) region mutational status: About half of the cases carry somatically mutated immunoglobulin V genes and hence derive from germinal center experienced memory B cells, whereas unmutated CLL derives from (likely CD5-positive) antigen-stimulated, but germinal center independent mature B cells. CLL precursor cells can be found years before diagnosis. The IGHV mutational status of CLL clones serves as one of the strongest prognostic markers. CLL often carries highly similar, i.e. stereotyped BCRs pointing to recognition of a restricted set of antigens. Indeed, the BCRs of many CLL clones are autoreactive for particular autoantigens, including the BCR itself. Pathogenic antigens are further drivers in CLL development. Thus, BCR-mediated signaling and antigen recognition play a major role in CLL pathogenesis.

17 December 2024 in Leukemia & Lymphoma
Verified
Journal Article
Open access
MDMaria Dampmann
Maria Dampmann
AKArtur Kibler
Artur Kibler
JTJulia von Tresckow
Julia von Tresckow
HRHans Christian Reinhardt
Hans Christian Reinhardt
RKRalf Küppers
Ralf Küppers
BBBettina Budeus
Bettina Budeus
Dual productive B-cell receptor (BCR) rearrangements have been repeatedly reported for chronic lymphocytic leukemia (CLL), but the standard population-based PCR analyses cannot distinguish whether these are bi-clonal CLL, or a monoclonal CLL with bi-allelic productive rearrangements. We investigated CLL cells by combined single-cell RNA and BCR sequencing. We identified two CLL clones using different immunoglobulin (Ig) heavy-chain V region genes (IGHV) genes and distinct Ig λ light chains. One clone is classified as Ig unmutated the other as mutated. The two CLL clones have distinct transcriptomes: Numerous genes were differentially expressed, with genes typical for unmutated or mutated CLL showing the expected representation in the two clones. Using PCR, cloning and Sanger sequencing of the IGHV rearrangements we detected both CLL clones over a period of three years without clinical progression of the CLL and thus giving insights into the disease biology of multi-clonal CLL.

4 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BBBettina Budeus
Bettina Budeus
MDMaria Dampmann
Maria Dampmann
AKArtur Kibler
Artur Kibler
BFBianca Faßbender
Bianca Faßbender
MBMartina Brauser
Martina Brauser
MSMarc Seifert
Marc Seifert
Single-cell RNAseq/VDJseq of tumor cells and normal residual B (NRB) cells from peripheral blood of chronic lymphocytic leukemia (CLL) patients identified three distinct tumor subsets according to phenotype, transcriptome, and immunoglobulin-V-gene (IgV)-mutations. Two major subsets share a typical CLL phenotype but differ in signaling, metabolism and cell cycle control, indicating that the circulating CLL pool is shaped by two states of activity. The third CLL subset shows the phenotype, proliferation capacity and extensive IgV-mutation diversity of normal CD5+ memory B cells. This previously unrecognized CLL tumor subset, which intermingles with NRB cells, was confirmed in 33 IgV-mutated (M-CLL) and IgV-unmutated (U-CLL) cases. Longitudinal IgV-mutation phylogenetics suggest that these NRB-associated CLL cells are generated pathogenetically early, mostly in germinal center reactions, and archive the individual IgV-diversification program, which is conserved throughout CLL course. Our study suggests that diversity is established early in CLL, that each tumor is composed of multiple subclonal expansions, and subclonal evolution can be depicted by IgV-mutation phylogenetics.

11 September 2026 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
MDMaria Dampmann
Maria Dampmann
SFSarah Flossdorf
Sarah Flossdorf
JKJulius Keyl
Julius Keyl
TLTheo Leitner
Theo Leitner
CKCyrus Khandanpour
Cyrus Khandanpour
CHChristine Hanoun
Christine Hanoun
Objectives: Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined. Methods: We conducted a retrospective, multi‐center analysis with 49 transplant‐eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto‐auto, allo‐auto, auto‐chimeric antigen receptor therapy). Results: The median follow‐up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies. Conclusions: Our data support recent recommendations advising treating patients with tandem transplantation regimes.